Raymond James Financial Inc. Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Raymond James Financial Inc. acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 61,671 shares of the company's stock, valued at approximately $3,845,000. Raymond James Financial Inc. owned about 0.18% of TransMedics Group as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Arizona State Retirement System raised its position in TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after purchasing an additional 184 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after purchasing an additional 317 shares during the period. Park Avenue Securities LLC raised its holdings in shares of TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock worth $548,000 after buying an additional 322 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of TransMedics Group by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after buying an additional 500 shares during the period. Finally, Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group in the 4th quarter valued at $31,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Down 0.7 %

TMDX opened at $93.50 on Friday. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The stock has a market capitalization of $3.16 billion, a PE ratio of 99.47 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a 50-day moving average price of $74.46 and a two-hundred day moving average price of $77.82.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on TMDX shares. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.